Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Organisation › Details

Synerkine Pharma B.V.

Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. Synerkine Pharma was founded in 2018 and has licensed the exclusive rights of its lead compound, a fusion protein of IL4 and IL10, from the University Medical Center Utrecht (UMCU), the Netherlands. This fusion protein targets common regulatory mechanisms in different types of chronic pain, and has unique properties as demonstrated by UMCU researchers, who showed that it is effective in reducing pain in multiple pre-clinical models. The ability to treat pain with drugs that mimic endogenous immune molecules and are based on a different mechanism of action than the current anti-analgesic drugs holds tremendous therapeutic and commercial potential. *

 

Period Start 2018-01-01 established (s-off
  Predecessor University Medical Center Utrecht (UMC Utrecht)
Products Industry fusion protein
  Industry 2 pain drug
Person Person Preusting, Hans (Synerkine Pharma 2018– CEO + Co-Founder)
     
Region Region Utrecht
  Country Netherlands
  City n. a. Utrecht
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Synerkine Pharma B.V.. (3/25/19). "Press Release: Synerkine Pharma Raises EUR3.3 Million in Series A Financing". Utrecht.
     
   
Record changed: 2020-08-04

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Synerkine Pharma B.V.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px




» top